{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:24:29Z","timestamp":1791343469288,"version":"4.3.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11864-019-0687-5","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T07:20:11Z","timestamp":1575530411000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Marginal Zone Lymphoma: State-of-the-Art Treatment"],"prefix":"10.1007","volume":"20","author":[{"given":"Ariel","family":"Sindel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Al-Juhaishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Yazbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"issue":"2","key":"687_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1046\/j.1365-2559.2002.01360.x","volume":"40","author":"B Maes","year":"2002","unstructured":"Maes B, De Wolf-Peeters C. Marginal zone cell lymphoma--an update on recent advances. Histopathology. 2002;40(2):117\u201326.","journal-title":"Histopathology"},{"issue":"8","key":"687_CR2","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","volume":"16","author":"JO Armitage","year":"1998","unstructured":"Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's lymphoma classification project. J Clin Oncol. 1998;16(8):2780\u201395.","journal-title":"J Clin Oncol"},{"issue":"12","key":"687_CR3","first-page":"1134","volume":"25","author":"F Bertoni","year":"2011","unstructured":"Bertoni F, Coiffier B, Salles G, Stathis A, Traverse-Glehen A, Thieblemont C, et al. MALT lymphomas: pathogenesis can drive treatment. Oncology (Williston Park). 2011;25(12):1134\u201342.","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"687_CR4","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/asheducation-2017.1.371","volume":"2017","author":"C Thieblemont","year":"2017","unstructured":"Thieblemont C. Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma. Hematology Am Soc Hematol Educ Program. 2017;2017(1):371\u20138.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"17","key":"687_CR5","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1182\/blood-2015-12-624304","volume":"127","author":"E Zucca","year":"2016","unstructured":"Zucca E, Bertoni F. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. Blood. 2016;127(17):2082\u201392.","journal-title":"Blood"},{"issue":"1\u20132","key":"687_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.beha.2016.09.002","volume":"30","author":"MQ Du","year":"2017","unstructured":"Du MQ. MALT lymphoma: genetic abnormalities, immunological stimulation and molecular mechanism. Best Pract Res Clin Haematol. 2017;30(1\u20132):13\u201323.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"8","key":"687_CR7","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1440-1827.2007.02128.x","volume":"57","author":"H Inagaki","year":"2007","unstructured":"Inagaki H. Mucosa-associated lymphoid tissue lymphoma: molecular pathogenesis and clinicopathological significance. Pathol Int. 2007;57(8):474\u201384.","journal-title":"Pathol Int"},{"issue":"1","key":"687_CR8","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2016.006","volume":"8","author":"S Perrone","year":"2016","unstructured":"Perrone S, D'Elia GM, Annechini G, Pulsoni A. Infectious Aetiology of marginal zone lymphoma and role of anti-infective therapy. Mediterr J Hematol Infect Dis. 2016;8(1):e2016006.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1\u20132","key":"687_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.beha.2016.07.002","volume":"30","author":"P Sriskandarajah","year":"2017","unstructured":"Sriskandarajah P, Dearden CE. Epidemiology and environmental aspects of marginal zone lymphomas. Best Pract Res Clin Haematol. 2017;30(1\u20132):84\u201391.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"8871","key":"687_CR10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/0140-6736(93)91409-F","volume":"342","author":"AC Wotherspoon","year":"1993","unstructured":"Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of helicobacter pylori. Lancet. 1993;342(8871):575\u20137.","journal-title":"Lancet"},{"issue":"8","key":"687_CR11","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/jnci\/djh102","volume":"96","author":"AJ Ferreri","year":"2004","unstructured":"Ferreri AJ, Guidoboni M, Ponzoni M, De Conciliis C, Dell'Oro S, Fleischhauer K, et al. Evidence for an association between chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst. 2004;96(8):586\u201394.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"687_CR12","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/0190-9622(91)70088-J","volume":"24","author":"C Garbe","year":"1991","unstructured":"Garbe C, Stein H, Dienemann D, Orfanos CE. Borrelia burgdorferi-associated cutaneous B cell lymphoma: clinical and immunohistologic characterization of four cases. J Am Acad Dermatol. 1991;24(4):584\u201390.","journal-title":"J Am Acad Dermatol"},{"issue":"6\u20137","key":"687_CR13","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1051\/medsci\/2004206-7638","volume":"20","author":"M Lecuit","year":"2004","unstructured":"Lecuit M, Suarez F, Lortholary O. Immunoproliferative small intestinal disease associated with campylobacter jejuni. Med Sci (Paris). 2004;20(6\u20137):638\u201340.","journal-title":"Med Sci (Paris)"},{"issue":"6","key":"687_CR14","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/1097-0142(197712)40:6<2941::AID-CNCR2820400628>3.0.CO;2-L","volume":"40","author":"PA Salem","year":"1977","unstructured":"Salem PA, Nassar VH, Shahid MJ, Hajj AA, Alami SY, Balikian JB, et al. \u201cMediterranean abdominal lymphoma,\u201d or immunoproliferative small intestinal disease. Part I: clinical aspects. Cancer. 1977;40(6):2941\u20137.","journal-title":"Cancer"},{"issue":"5","key":"687_CR15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/00130404-200509000-00003","volume":"11","author":"PA Salem","year":"2005","unstructured":"Salem PA, Estephan FF. Immunoproliferative small intestinal disease: current concepts. Cancer J. 2005;11(5):374\u201382.","journal-title":"Cancer J"},{"issue":"2","key":"687_CR16","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/annonc\/mdl388","volume":"18","author":"L Arcaini","year":"2007","unstructured":"Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol. 2007;18(2):346\u201350.","journal-title":"Ann Oncol"},{"issue":"2","key":"687_CR17","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood.V90.2.766","volume":"90","author":"B Royer","year":"1997","unstructured":"Royer B, Cazals-Hatem D, Sibilia J, Agbalika F, Cayuela JM, Soussi T, et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood. 1997;90(2):766\u201375.","journal-title":"Blood"},{"issue":"1","key":"687_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1210\/jcem.87.1.8156","volume":"87","author":"C Thieblemont","year":"2002","unstructured":"Thieblemont C, Mayer A, Dumontet C, Barbier Y, Callet-Bauchu E, Felman P, et al. Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metab. 2002;87(1):105\u201311.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3\u20134","key":"687_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12308-017-0302-2","volume":"10","author":"MI Schreuder","year":"2017","unstructured":"Schreuder MI, van den Brand M, Hebeda KM, Groenen P, van Krieken JH, Scheijen B. Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma. J Hematop. 2017;10(3\u20134):91\u2013107.","journal-title":"J Hematop"},{"issue":"1","key":"687_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/cncr.27704","volume":"119","author":"A Heilgeist","year":"2013","unstructured":"Heilgeist A, McClanahan F, Ho AD, Witzens-Harig M. Prognostic value of the follicular lymphoma international prognostic index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients. Cancer. 2013;119(1):99\u2013106.","journal-title":"Cancer"},{"issue":"12","key":"687_CR21","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","volume":"130","author":"C Thieblemont","year":"2017","unstructured":"Thieblemont C, Cascione L, Conconi A, Kiesewetter B, Raderer M, Gaidano G, et al. A MALT lymphoma prognostic index. Blood. 2017;130(12):1409\u201317.","journal-title":"Blood"},{"key":"687_CR22","doi-asserted-by":"crossref","unstructured":"Alderuccio JP, Zhao W, Desai A, Gallastegui N, Ramdial J, Kimble E, et al. Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution. J Clin Oncol. 2018:JCO1800138.","DOI":"10.1200\/JCO.18.00138"},{"issue":"11","key":"687_CR23","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","volume":"26","author":"A Conconi","year":"2015","unstructured":"Conconi A, Franceschetti S, Aprile von Hohenstaufen K, Margiotta-Casaluci G, Stathis A, Moccia AA, et al. Histologic transformation in marginal zone lymphomasdagger. Ann Oncol. 2015;26(11):2329\u201335.","journal-title":"Ann Oncol"},{"issue":"8965","key":"687_CR24","first-page":"1591","volume":"345","author":"E Bayerdorffer","year":"1995","unstructured":"Bayerdorffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of helicobacter pylori infection. MALT Lymphoma Study Group Lancet. 1995;345(8965):1591\u20134.","journal-title":"MALT Lymphoma Study Group Lancet"},{"key":"687_CR25","first-page":"6794848","volume":"2016","author":"JS Kim","year":"2016","unstructured":"Kim JS, Kang SH, Moon HS, Sung JK, Jeong HY. Clinical outcome of eradication therapy for gastric mucosa-associated lymphoid tissue lymphoma according to H. pylori infection status. Gastroenterol Res Pract. 2016;2016:6794848.","journal-title":"Gastroenterol Res Pract"},{"issue":"24","key":"687_CR26","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1200\/JCO.2011.41.4466","volume":"30","author":"AJ Ferreri","year":"2012","unstructured":"Ferreri AJ, Govi S, Pasini E, Mappa S, Bertoni F, Zaja F, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol. 2012;30(24):2988\u201394.","journal-title":"J Clin Oncol"},{"issue":"16","key":"687_CR27","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1002\/cncr.25226","volume":"116","author":"JS Goda","year":"2010","unstructured":"Goda JS, Gospodarowicz M, Pintilie M, Wells W, Hodgson DC, Sun A, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010;116(16):3815\u201324.","journal-title":"Cancer"},{"issue":"6","key":"687_CR28","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.3109\/10428194.2014.975801","volume":"56","author":"IS Lossos","year":"2015","unstructured":"Lossos IS, Fabregas JC, Koru-Sengul T, Miao F, Goodman D, Serafini AN, et al. Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. Leuk Lymphoma. 2015;56(6):1750\u20135.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"687_CR29","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/14656566.2019.1582643","volume":"20","author":"T Al Juhaishi","year":"2019","unstructured":"Al Juhaishi T, Yazbeck V. Choosing the right pharmacotherapy for non-Hodgkin's lymphoma: does one size fit all? Expert Opin Pharmacother. 2019;20(7):773\u20135.","journal-title":"Expert Opin Pharmacother"},{"issue":"30","key":"687_CR30","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","volume":"33","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, et al. Randomized phase II trial comparing Obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol. 2015;33(30):3467\u201374.","journal-title":"J Clin Oncol"},{"issue":"17","key":"687_CR31","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","volume":"35","author":"E Zucca","year":"2017","unstructured":"\u2022\u2022 Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, et al. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus Chlorambucil versus either Chlorambucil or rituximab monotherapy. J Clin Oncol. 2017;35(17):1905\u201312. First large randomized, 3-arms phase III trial that showed superior efficacy of the combination of chlorambucil and rituxian to single agent alone.","journal-title":"J Clin Oncol"},{"issue":"4","key":"687_CR32","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00277-011-1337-6","volume":"91","author":"HJ Kang","year":"2012","unstructured":"Kang HJ, Kim WS, Kim SJ, Lee JJ, Yang DH, Kim JS, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: consortium for improving survival of lymphoma (CISL) study. Ann Hematol. 2012;91(4):543\u201351.","journal-title":"Ann Hematol"},{"issue":"19","key":"687_CR33","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944\u201352.","journal-title":"Blood"},{"issue":"3","key":"687_CR34","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1016\/S2352-3026(14)00021-0","volume":"1","author":"A Salar","year":"2014","unstructured":"Salar A, Domingo-Domenech E, Panizo C, Nicolas C, Bargay J, Muntanola A, et al. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2014;1(3):e104\u201311.","journal-title":"Lancet Haematol"},{"issue":"15","key":"687_CR35","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1182\/blood-2017-07-795302","volume":"130","author":"A Salar","year":"2017","unstructured":"Salar A, Domingo-Domenech E, Panizo C, Nicolas C, Bargay J, Muntanola A, et al. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood. 2017;130(15):1772\u20134.","journal-title":"Blood"},{"issue":"5","key":"687_CR36","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/bjh.15641","volume":"183","author":"E Iannitto","year":"2018","unstructured":"\u2022 Iannitto E, Bellei M, Amorim S, Ferreri AJM, Marcheselli L, Cesaretti M, et al. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA\/IELSG36 study. Br J Haematol. 2018;183(5):755\u201365. A large phase II trial studying the efficacy of BR specifically in splenic marginal zone lymphoma.","journal-title":"Br J Haematol"},{"issue":"8","key":"687_CR37","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17(8):1081\u201393.","journal-title":"Lancet Oncol"},{"key":"687_CR38","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/hon.2437_136","volume":"35","author":"MHE Herold","year":"2017","unstructured":"Herold MHE, Janssens A, et al. Immunochemotherapy with obinutuzumab or rituximab in a subset of patients in the randomised gallium trial with previously untreated marginal zone lymphoma (MZL). Hematol Oncol. 2017;35:146\u20137.","journal-title":"Hematol Oncol"},{"issue":"6","key":"687_CR39","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjh.14007","volume":"173","author":"ME Williams","year":"2016","unstructured":"Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: eastern cooperative oncology group protocol E4402. Br J Haematol. 2016;173(6):867\u201375.","journal-title":"Br J Haematol"},{"issue":"5","key":"687_CR40","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3324\/haematol.2008.001537","volume":"94","author":"M Troch","year":"2009","unstructured":"Troch M, Jonak C, Mullauer L, Puspok A, Formanek M, Hauff W, et al. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009;94(5):738\u201342.","journal-title":"Haematologica"},{"issue":"14","key":"687_CR41","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","volume":"37","author":"JP Leonard","year":"2019","unstructured":"\u2022\u2022 Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, et al. AUGMENT: a phase III study of Lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188\u201399. Randomized, phase 3 trial that led to approval of lenalidomide and rituximab in relapsed\/refractory follicular lymphoma and marginal zone lymphomas.","journal-title":"J Clin Oncol"},{"issue":"5","key":"687_CR42","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/bjh.15843","volume":"185","author":"MR Becnel","year":"2019","unstructured":"Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, et al. Lenalidomide plus rituximab (R(2) ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. 2019;185(5):874\u201382.","journal-title":"Br J Haematol"},{"issue":"16","key":"687_CR43","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","volume":"129","author":"A Noy","year":"2017","unstructured":"\u2022\u2022 Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma. Blood. 2017;129(16):2224\u201332. Phase 2 trial that lead to the FDA-approval of ibrutinib for patients with relapse\/refractory MZ.","journal-title":"Blood"},{"issue":"11","key":"687_CR44","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008\u201318.","journal-title":"N Engl J Med"},{"issue":"9","key":"687_CR45","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","volume":"28","author":"M Dreyling","year":"2017","unstructured":"\u2022 Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28(9):2169\u201378. Phase 2 trial that lead to FDA-breakthrough designation for copanlisib for patients with relapse\/refractory MZL.","journal-title":"Ann Oncol"},{"issue":"11","key":"687_CR46","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/JCO.18.00915","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline SE, Mayer J, et al. DYNAMO: a phase II study of Duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2019;37(11):912\u201322.","journal-title":"J Clin Oncol"},{"issue":"16","key":"687_CR47","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1182\/blood-2018-08-867499","volume":"133","author":"A Forero-Torres","year":"2019","unstructured":"Forero-Torres A, Ramchandren R, Yacoub A, Wertheim MS, Edenfield WJ, Caimi P, et al. Parsaclisib, a potent and highly selective PI3Kdelta inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019;133(16):1742\u201352.","journal-title":"Blood"},{"key":"687_CR48","doi-asserted-by":"publisher","first-page":"7506","DOI":"10.1200\/JCO.2019.37.15_suppl.7506","volume":"37","author":"NSF Fowler","year":"2019","unstructured":"\u2022 Fowler NSF, Jurczak W, et al. Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed\/refractory marginal zone lymphoma: a multicenter, open label, registration directed phase II study. J Clin Oncol. 2019;37:7506. Phase 2 trial that lead to FDA-breakthrough designation for umbralisib for patients with relapse\/refractory MZL.","journal-title":"J Clin Oncol"},{"issue":"8","key":"687_CR49","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of Venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826\u201333.","journal-title":"J Clin Oncol"},{"issue":"9","key":"687_CR50","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1093\/annonc\/mdy256","volume":"29","author":"S de Vos","year":"2018","unstructured":"de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, et al. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol. 2018;29(9):1932\u20138.","journal-title":"Ann Oncol"},{"issue":"22","key":"687_CR51","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","volume":"36","author":"BD Cheson","year":"2018","unstructured":"\u2022 Cheson BD, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received Obinutuzumab plus Bendamustine induction and Obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018;36(22):2259\u201366. First randomized phase 3 trial to show improvement in overall survival with maintenance obinutuzumab in patients with rituximab-refractory indolent non-hodgkin\u2019s lymphoma.","journal-title":"J Clin Oncol"},{"key":"687_CR52","doi-asserted-by":"crossref","unstructured":"Andorsky DJCM, Yacoub A, et al. Magnify: phase IIIb interim analysis of induction R2 followed by maintenance in patients with relapsed\/refractory indolent non-Hodgkin lymphoma. ASCO Annual Meeting. 2019.","DOI":"10.1016\/j.htct.2020.10.372"},{"key":"687_CR53","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1182\/blood-2017-04-737338","volume":"130","author":"MSFI Davids","year":"2017","unstructured":"Davids MSFI. O'Connor OA, et al an integrated safety analysis of the next generation PI3K\u03b4 inhibitor Umbralisib (TGR-1202) in patients with relapsed\/refractory lymphoid malignancies. Blood. 2017;130:4037.","journal-title":"Blood"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0687-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-019-0687-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0687-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T20:25:06Z","timestamp":1650486306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-019-0687-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["687"],"URL":"https:\/\/doi.org\/10.1007\/s11864-019-0687-5","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"5 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Ariel Sindel declares that he has no conflict of interest.Taha Al-Juhaishi declares that he has not conflict of interest.Victor Yazbeck has received research funding through grants from Gilead and has received honoraria from Pharmacyclics, Celgene, and Seattle Genetics for service on advisory boards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"90"}}